Skip to content
Study details
Enrolling now

Clozapine Trial to Prevent Violence in Schizophrenia

New York State Psychiatric Institute
NCT IDNCT05208190ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

280

Study length

about 5 years

Ages

18–65

Locations

7 sites in CA, GA, MD +2

What this study is about

Researchers are testing whether clozapine, a medication, can help prevent violence in people with schizophrenia who have a history of violent acts. Participants will be randomly assigned to receive either clozapine or their usual treatment (TAU). The trial will last for 1809 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Clozapine
  • 2.Take treatment as usual

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

clozapine (Atypical antipsychotic; blocks dopamine and serotonin (higher efficacy for refractory schizophrenia))

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Positive symptoms and substance use

Body systems

Psychiatry / Mental Health